Por Renan Filho · 2026-10-10
**Lead**
A new coronavirus variant, named XFG, has been identified in the United Kingdom, with the first confirmed cases reported in England and Scotland over the past week. The UK Health Security Agency (UKHSA) has classified XFG as a variant under monitoring, noting that it carries a combination of mutations seen in previous Omicron sublineages. While early data suggest the strain may be more transmissible than the currently dominant JN.1 variant, there is no evidence so far that it causes more severe illness. Health authorities are urging the public to remain vigilant and to follow standard precautions, including staying up to date with vaccinations.
**Context**
The XFG variant was first detected in wastewater samples in London in late September, with genomic sequencing confirming its presence in clinical cases shortly after. According to the UKHSA’s latest technical briefing, XFG is a recombinant strain, meaning it emerged from the mixing of two different Omicron subvariants. It shares several spike protein mutations with the BA.2.86 lineage, which previously drove a wave of infections in the UK, but also carries additional changes that may help it evade immune responses more effectively.
As of early October, fewer than 100 cases have been confirmed through PCR testing, but the UKHSA estimates that the true number could be higher due to limited sequencing capacity. The variant has also been reported in small numbers in the United States, Germany, and Australia, suggesting international spread. The World Health Organization has not yet assigned a Greek letter label to XFG, as it remains under assessment.
Symptoms reported by patients infected with XFG appear similar to those of other Omicron variants. The most common include a runny or blocked nose, sore throat, headache, persistent cough, fatigue, and muscle aches. Some individuals have also reported gastrointestinal symptoms such as diarrhoea and nausea. Loss of taste or smell, once a hallmark of earlier strains, is less frequently reported with XFG. The UKHSA emphasises that symptoms can vary widely depending on a person’s age, vaccination status, and underlying health conditions.
**Analysis**
The emergence of XFG underscores the ongoing evolution of SARS-CoV-2 and the need for sustained surveillance. Unlike the early pandemic waves, the UK now has a high level of population immunity from both vaccination and prior infection. However, each new variant poses a risk of increased transmissibility or immune escape, which could lead to a surge in cases and put pressure on the NHS, particularly during the winter months when respiratory viruses circulate widely.
Public health experts have noted that the current vaccines, which are updated to target the JN.1 lineage, may offer reduced protection against XFG due to its distinct mutations. The UKHSA is conducting laboratory studies to assess neutralisation levels. In the meantime, the agency recommends that eligible individuals receive their autumn booster dose, as even partial protection can reduce the risk of severe disease. The NHS has also reminded the public that antiviral treatments remain available for high-risk patients who test positive.
Another concern is the potential for XFG to cause a new wave of infections in care homes and hospitals, where vulnerable populations are concentrated. The UKHSA has advised healthcare facilities to reinforce infection control measures, including mask-wearing in clinical areas and improved ventilation. The government has not announced any new restrictions, but officials are closely monitoring hospital admission data.
**Fontes**
- UK Health Security Agency (UKHSA) Technical Briefing on SARS-CoV-2 variants, October 2026. - World Health Organization (WHO) weekly epidemiological update on COVID-19, October 2026. - NHS England guidance on COVID-19 symptoms and treatments. - Reports from Public Health Scotland on variant surveillance.